A systematic review was conducted to determine whether initial screening characteristics of women with normogonadotrophic anovulatory infertility predict clinically signi®cant outcomes of ovulation induction with gonadotrophins, and to obtain pooled estimates of their predictive value through meta-analysis. Only those studies in which pre-treatment screening characteristics (such as body mass index, serum LH and androgens, insulin sensitivity and ultrasound appearance of ovaries) were related to outcome parameters (such as total amount of FSH administered, cancellation, ovulation, pregnancy and miscarriage), were included in this analysis. Thirteen studies ful®lled the inclusion criteria. A positive association was seen in all studies between the level of obesity (de®nition applied as assessed by individual studies) and total amount of FSH administered [weighted mean difference (WMD) of 771 IU (95% con®dence interval (CI): 700±842)]. Pooled odds ratios (OR) of 1.86 (95% CI: 1.13±3.06) and 0.44 (95% CI: 0.31±0.61) were found between obesity with cancellation and ovulation respectively. Pooled analysis did not show a signi®cant association between obesity and pregnancy rate. The pooled OR for obese versus non-obese women and miscarriage rate was signi®cant [3.05 (95% CI: 1.45±6.44)]. Association measures between insulin resistance (de®n-ition applied as assessed by individual studies) and total amount of FSH administered produced a WMD of 351 (95% CI: 73±630) IU. A pooled OR of 0.29 (95% CI: 0.10±0.80) was found for insulin resistance with pregnancy rate. The pooled OR for insulin resistance (hyperinsuliaemia versus normoinsuliaemia) and miscarriage rate was not signi®cant. A pooled OR of 1.04 (95% CI: 1.01±1.07) was found for LH (IU/l) with pregnancy rate. The pooled OR for LH and miscarriage rate was not signi®cant. Finally, pooled analysis did not ®nd a signi®cant association between testosterone and pregnancy rate. In conclusion, the best available evidence, though limited, suggests that the most clinically useful predictors of gonadotrophin ovulation induction outcome in normogonadotrophic women are obesity and insulin resistance.
Introduction
Chronic anovulation presents with amenorrhoea or oligomenorhoea and can be classi®ed on the basis of serum FSH and estradiol (E 2 ) levels. Hypogonadotrophic anovulation, low levels of gonadotrophins and negligible estrogen activity, is also referred to as (World Health Organization (WHO) group 1. Hypergonadotrophic anovulation is characterized by elevated gonadotrophin levels and low E 2 (WHO group 3) (Lunenfeld and Insler, 1974; ESHRE Capri Workshop Group, 1995; Rowe et al., 2000) .
Normogonadotrophic anovulation (FSH and E 2 levels within the normal range) (WHO group 2) represents the most common form of ovarian dysfunction and is a frequent cause of infertility (Laven et al., 2002; Rowe et al., 2000) .
Clomiphene citrate has been used worldwide as the medication of ®rst choice for the treatment of these women, because it is safe, convenient, cheap, and reasonably effective. The risk of developing ovarian hyperstimulation syndrome (OHSS) and multiple gestation is limited (2±3%) (Imani et al., 1999) . However, a signi®cant proportion (23%) of women remain anovulatory following clomiphene citrate (Imani et al., 1998) . A cumulative pregnancy rate of 73% is reported in ovulatory clomiphene citratetreated women (Imani et al., 1999) .
Induction of ovulation using exogenous gonadotrophins is generally indicated in patients with normogonadotrophic anovulatory infertility who have failed to ovulate or to conceive during previous clomiphene citrate treatment (Schwartz and Jewelewicz, 1981; Lunenfeld et al., 1985; Insler, 1988; Kelly and Jewelewicz, 1990; Franks and Gilling-Smith, 1994; Fauser and Van Heusden, 1997) . Since the early 1960s, many anovulatory patients have been treated with hMG and hCG to induce ovulation. This treatment modality has been proven to be effective, but the risks of OHSS (Stephenson, 1991; Navot et al., 1992) and multiple pregnancies are considerably increased (Schenker et al., 1981; Fauser and Van Heusden, 1997) .
Recent studies have focused on the prediction of ovulation induction outcome based upon initial screening characteristics of WHO 2 anovulatory infertile women (Imani et al., 1998 (Imani et al., , 1999 (Imani et al., , 2002a Mulders et al., 2003) . It could be demonstrated that some clinical, sonographic and endocrine characteristics are predictive of ovulation and conception during clomiphene citrate treatment (Imani et al., 1998 (Imani et al., , 1999 (Imani et al., , 2000 (Imani et al., , 2002a . Outcome parameters of gonadotrophin treatment in these women correlated with woman's age, ovarian response to preceding clomiphene citrate medication, body mass index (BMI), the mean follicle number assessed by ultrasound, serum levels of FSH, testosterone, androstenedione, and initial insulin-like-growth factor-I (IGF-I) (Imani et al., 2002b; Mulders et al., 2003) .
The aim of gonadotrophin ovulation induction in anovulatory infertility is healthy live-birth, preferably from a singleton pregnancy. This is often hard to achieve despite the recent introduction of low-dose incremental or decremental regimens (Fauser and Van Heusden, 1997 ). An individualized treatment regimen, based on valid outcome predictors, might optimize ovulation induction strategies by improving the balance between success and complications. The existing literature concerning the prediction of outcome is limited and ambiguous. Some studies observe signi®cant associations, whereas others fail to do so. Therefore, a systematic review was undertaken to establish more ®rmly which screening parameters are predictive of outcome of gonadotrophin induction of ovulation.
Materials and methods
The objectives of this review were to determine whether screening criteria applied to women with normogonadotrophic anovulatory infertility, predict clinically signi®cant outcomes of ovulation induction with gonadotrophins, and to obtain pooled estimates of their predictive value through meta-analysis.
Criteria for considering studies for this review Studies reporting gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility [WHO 2, including polycystic ovary syndrome (PCOS)] were considered for inclusion if they provided speci®c information on: the regimens and type of gonadotrophin administered, e.g. standard protocol, step-up protocol, step-down protocol, hMG, urinary-derived (u)FSH and recombinant (r)FSH. The following primary outcome measures were sought: monofollicular growth [arbitrarily de®ned as one follicle >15 mm on the day of hCG (van Santbrink and Fauser, 1997) ], total amount of gonadotrophins administered on the day of hCG in international units (IU), cancellation rate (cycle where there is no hCG administered), ovulation rate (as con®rmed by an increased serum progesterone level (>20 nmol/l) in the luteal phase), pregnancy rate (per cycle or per patient) (de®ned as a positive urinary pregnancy test) and miscarriage rate (sonographic assessment of absence of an intrauterine gestational sac with heart beat at 12 weeks amenorrhoea). The following screening characteristics were also sought: age (years), cycle history (oligo-or amenorrhoea), BMI (kg/m 2 ), response during previous clomiphene citrate treatment [clomiphene resistant anovulation (CRA)/clomiphene citrate failure (CCF)], ovarian volume (ml), total number of follicles (both ovaries) (Pache et al., 1992) , ovarian stroma echogenicity (Dewailly et al., 1994) , serum levels of testosterone, androstenedione, LH, LH/FSH, fasting insulin and glucose. Inclusion was limited to studies in which outcome parameters were related to pre-treatment screening characteristics.
Search strategy for the identi®cation of studies Studies reporting the prediction of outcomes following gonadotrophin induction were initially identi®ed through a handsearch (no speci®c criteria: papers at hand were considered). The wide variety of key words used in these reports provided the foundation for the ®nal search strategy. It consisted of: (i) a Medline search by means of MESH headings (in the following order): (follicle stimulating hormone [majr] OR menotrophins [majr] ) AND`female genital diseases and pregnancy complications' [Majr] and (ii) a check of the bibliographies of identi®ed studies. ( to October 2002 . For 474 titles it was clear that population or intervention did not ful®l the selection criteria. To verify whether it was appropriate to exclude such articles based solely on titles, one of us (A.M.) read 10 of the 474 articles. None ful®lled the inclusion justifying this identi®cation strategy. The remaining 157 articles were then read by one author (A.M.). Twenty-three studies ful®lled the selection criteria. All of their bibliographies were checked. This identi®ed one additional study for inclusion.
Identi®cation
Twenty-four potentially relevant studies were read by all authors and 13 were included. There were no disagreements between authors regarding the inclusion of studies.
Methods of the review
The following information was extracted from the potentially relevant studies: study characteristics, speci®ed as observational, cohort, crossover, consecutive or randomized, multicentre or not, method of randomization, number of patients/cycles (randomized, excluded and analysed), duration, timing and location of the study. Patient characteristics were recorded: de®nition of normogonadotrophic anovulatory infertility (WHO 2 including PCOS) (clinical, biochemical, ultrasonographic markers or combination of the former), de®nition and duration of infertility, age, investigative work-up, other causes of infertility and previously administered treatment(s), in particular whether previous treatment with clomiphene citrate had been tried and how CRA or CCF was de®ned. Finally, the outcome measures and their speci®c de®nitions were also recorded: total amount of exogenous FSH administered (IU), duration of administration of exogenous FSH (days), the number of cancelled cycles, the number of cycles with multi-or monofollicular growth, the number of ovulatory cycles, the number of patients pregnant and not pregnant, miscarriage rate, multiple pregnancy rate and OHSS rate. A study had to give either a direct measure of association between predictor and outcome variables or present data that allowed for the calculation of such a measure. Studies reporting relationships between initial screening characteristics and outcome parameters of ovulation induction as measures of association (odds ratios: OR) and studies from which measures of association could be derived from the data given were included. For example, if a study reported the mean and SD of an outcome variable (eg. cancellation rate) for obese and for lean women separately, the OR of cancellation rate for obesity could be calculated assuming a normal distribution of the outcome variable in both groups, by the formula: ln(OR) = (mean obese ± mean lean )/ (pooled variance in obese and lean ).
Results

Studies excluded
Eleven potentially relevant studies were excluded (Table I) . These included application of modi®ed stimulation schemes [Norfolk (1, 3, 5) regimen or administration of 150 IU every other day] (Ginsburg and Hardiman, 1991; Remorgida et al., 1991) , application of modi®ed controlled ovarian hyperstimulation followed by intrauterine and/or intraperitoneal insemination for PCOS and normo-ovulatory patients (Zullo et al., 1996) , and comparison of two different stimulation regimens for a different subset of patients (repetitive cycles, not equally distributed) (Shoham et al., 1991) .
Six studies stated insuf®cient data to allow analysis: only Plevels were noted for signi®cant and non-signi®cant prediction of duration of treatment by screening parameters (Coelingh Bennink et al., 1998) , insuf®cient data were provided to calculate OR (respectively age versus conception) (Ginsburg and Hardiman, 1991) , no clear statement of the background of LH levels supplied , only data of LH pre-treatment versus ovulation for a subset of patients (Polson et al., 1987) , no original data of LH levels (separately for pregnant and non-pregnant women) (Strowitzki et al., 1994) . Finally, data for different subsets of patients (WHO 1 and 2) were not provided separately (Fluker et al., 1994) .
In one study (Abdel et al., 1990 ), Pearson's correlation statistics showed a signi®cant positive correlation between the BMI and the dose of gonadotrophins (r = 0.4666; P < 0.001). This dose correlated negatively with ovarian volume (r = ±0.1958; P = 0.01). Since these correlation coef®cients could not be incorporated in the pooled analysis, these data were not included.
One study (Imani et al., 2002b) provided signi®cant correlations between the amount of exogenous FSH required for ovarian response [sonographic visualisation of a follicle b10 mm (Pache et al., 1990) ] and initial clinical, sonographic and endocrine screening characteristics. Four of these parameters (i.e. ovarian response to clomiphene citrate medication (CRA), BMI, initial serum levels of FSH and free IGF-I) were included in the multivariate model to predict the FSH response dose (i.e. the amount of exogenous FSH required for ovarian response). Since this study only reported one speci®c outcome parameter that was not considered in the review, this study was excluded from the pooled analysis.
Methodological quality of included studies
A total of 13 studies was included in the current review (Table II) Hamilton-Fairley et al., 1992; McClure et al., 1992 McClure et al., , 1993 Dale et al., 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Dale et al., 1998; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . Some researchers performed several studies concerning outcome of ovulation induction in the same patient group of interest Hamilton-Fairley et al., 1992; McClure et al., 1992 McClure et al., , 1993 Dale et al., 1993 Dale et al., , 1998 White et al., 1996) . However, these studies appeared to include a different subset of patients Dale et al., 1993 Dale et al., , 1998 White et al., 1996) or the focus (screening characteristic versus outcome parameter) of the studies was different Hamilton-Fairley et al., 1992; McClure et al., 1992 McClure et al., , 1993 White et al., 1996) .
Description of participants
The de®nitions of normogonadotrophic anovulatory infertility (WHO 2) and PCOS varied between centres, as detailed in Table II . Patients suffering from WHO 2 anovulatory infertility were included (Farhi et al., 1993; Balasch et al., 1996; Yarali et al., 1999) . The most comprehensive de®nition of PCOS speci®ed as a combination of clinical features (oligoamenorrhoea), biochemical parameters (increased androgen concentrations) and polycystic appearance of ovaries on ultrasound scan (enlarged ovaries with multiple small follicles), was used in a number of studies (McClure et al., 1992; Fulghesu et al., 1997; Vicino et al., 2000) . Various combinations of clinical, biochemical and ultrasonic ®ndings were also used: ultrasound and clinical or biochemical HamiltonFairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Strowitzki et al., 1998), clinical and ultrasound and /or biochemical (McClure et al., 1993) , or clinical and ultrasound (White et al., 1996) . According to these de®nitions, oligoamenorrhoea is not present in all patients per se (McClure et al., 1992; Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; Balasch et al., 1996; Strowitzki et al., 1998) .
The extent of the infertility work-up was stated in all studies Hamilton-Fairley et al., 1992; McClure et al., 1992 McClure et al., , 1993 Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . This consisted most commonly of a semen analysis and a hysterosalpingography and/or laparoscopic inspection. Twelve studies included only couples with a normal semen analysis Hamilton-Fairley et al., 1992; McClure et al., 1992 McClure et al., , 1993 Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; Balasch et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . In all studies, tubal patency (at least one open tube) was con®rmed (Sagle et 1992, 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Vicino et al., 2000) . In one study, donor sperm (one patient) were used because of co-existing male factor infertility . Except for one study (White et al., 1996) , the patients of interest either had remained anovulatory after clomiphene citrate treatment, or had failed to conceive despite ovulating during clomiphene citrate treatment. A wide variation in the de®nition of clomiphene citrate-resistant anovulation and failure was used. In two studies, ovarian wedge resection or ovarian electrocauterization had been performed before gonadotrophin induction of ovulation (Dale et al., 1993 .
In three studies, patients with increased BMI levels were excluded from treatment: BMI >28 kg/m 2 White et al., 1996) and BMI >30 kg/m 2 .
Description of interventions
The step-up regimen was applied according to the following protocol: a starting dose of 75 IU per day and a ®rst dose increase of 75 IU per day after 5±7 days (Farhi et al., 1993) . Various alternatives of this protocol were reported (McClure et al., 1992 (McClure et al., , 1993 Fulghesu et al., 1997; Vicino et al., 2000) . Others used the step-up regimen according to the following protocol: starting dose of 50±75 IU per day, a ®rst dose increase of 37.5 IU per day after 14 days and a subsequent dose increase of 37.5 IU per day HamiltonFairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Balasch et al., 1996; White et al., 1996; Yarali et al., 1999) . Strowitzky et al. utilized a variation of this regimen. In some studies the starting dose was adjusted in the subsequent (>1) cycle performed (McClure et al., 1992; Balasch et al., 1996; White et al., 1996; Yarali et al., 1999; Vicino et al., 2000) .
The following preparations of gonadotrophins were used: hMG Hamilton-Fairley et al., 1992; McClure et al., 1992; Farhi et al., 1993; White et al., 1996) , uFSH Hamilton-Fairley et al., 1992; McClure et al., 1992; Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) and rFSH (Strowitzki et al., 1998; Yarali et al., 1999) . Only one study compared gonadotrophin-only treatment (uFSH/ hMG) with a combined regimen (hMG and the concomitant administration of a GnRH agonist) (Farhi et al., 1993) . Besides gonadotrophin induction of ovulation, electrocautery was also performed in one study (Vicino et al., 2000) .
Description of outcome measures
In six studies the number of cycles with monofolllicular development was not reported (McClure et al., 1992 (McClure et al., , 1993 Farhi et al., 1993; White et al., 1996; Fulghesu et al., 1997; Vicino et al., 2000) . The de®nition of monofollicular growth varied from one follicle >15 mm and one follicle >17 mm (Balasch et al., 1996) in diameter on the day of hCG. In ®ve studies the de®nition used was not clearly stated Presence of polycystic ovaries based on published criteria (Adams et al., 1985 (Adams et al., , 1986 .
c Serum oestradiol levels of between 200 and 1500 pg/ml per follicle >15 mm. PCOS = polycystic ovary syndrome; BMI = body mass index; CRA = clomiphene-resistant anovulation; OHSS = ovarian hyperstimulation syndrome; WHO = World Health Organization; CCF = clomiphene citrate failure; IGF = insulin-like growth factor; SHBG = sex hormone-binding globulin; COH = controlled ovarian hyperstimulation; IUI = intrauterine insemination; IPI = intraperitoneal insemination; TVS-PCO = transvaginal sonography polycystic ovaries; FAI = free androgen index de®ned as 100 Q T/SHBG; GOI = gonadotrophin ovulation induction; p/s = primary/secondary; endo/histo = endocrine histologic criteria; pt/cy = patient/cycle. Presence of polycystic ovaries based on previously published criteria (Adams et al., 1985 (Adams et al., , 1986 ).
For abbreviations see Table I . Hamilton-Fairley et al., 1992; Dale et al., 1993; Strowitzki et al., 1998; Yarali et al., 1999) . Only seven studies reported the number of cycles with monofollicular growth Hamilton-Fairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Balasch et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999) . The total amount of gonadotrophins administered per cycle McClure et al., 1992 McClure et al., , 1993 Dale et al., 1993; Farhi et al., 1993; White et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) or the mean total quantity of gonadotrophins to induce ovulation or achieve follicular maturation Balasch et al., 1996; Fulghesu et al., 1997; Dale et al., 1998) was provided for all studies in ampoules or IU. For one study (McClure et al., 1992 ) the total amount of gonodotrophins administered was deduced from a ®gure illustration. A conversion to IU was made for those studies reporting the total dose in ampoules Hamilton-Fairley et al., 1992; Farhi et al., 1993; White et al., 1996; Strowitzki et al., 1998; Vicino et al., 2000) .
Criteria for cycle cancellation were based on the number of follicles developed and/or serum E 2 levels. In ®ve studies, cycles were cancelled in case of multifollicular growth (b4 follicles b15 mm) Hamilton-Fairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 White et al., 1996; Yarali et al., 1999) . In four studies, cycles were cancelled because of multifollicular growth or absence of response (Balasch et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . Finally, three studies cancelled treatment cycles based on multifollicular growth and/or increased serum E 2 levels (McClure et al., 1992 (McClure et al., , 1993 Farhi et al., 1993) . One study did not provide information on criteria for cycle cancellation (Fulghesu et al., 1997) . Only nine studies reported the number of cancelled cycles McClure et al., 1992; Dale et al., 1993 Dale et al., , 1998 Balasch et al., 1996; White et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) .
Criteria for ovulation were based on the assessment of serum progesterone levels Dale et al., 1993; White et al., 1996; Dale et al., 1998; Yarali et al., 1999) , or ultrasound (Strowitzki et al., 1998) or both Fulghesu et al., 1997; Vicino et al., 2000) . Four studies did not provide information concerning con®rmation of ovulation (McClure et al., 1992 (McClure et al., , 1993 Farhi et al., 1993; Balasch et al., 1996) . A total of 11 studies reported the number of ovulatory cycles Hamilton-Fairley et al., 1992; McClure et al., 1992; Dale et al., 1993; Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) .
Explicit details of the de®nition of pregnancy were given by using serum hCG Strowitzki et al., 1998; Yarali et al., 1999) , ultrasound (Balasch et al., 1996; Vicino et al., 2000) , serum hCG and ultrasound or ultrasound and/or histological veri®cation (Dale et al., 1993 . Two studies speci®cally stated the presence of a clinical pregnancy Yarali et al., 1999) . Finally, one study only provided data on the de®nition of a clinical pregnancy (i.e. intrauterine gestational sac and fetal heart beat) (Vicino et al., 2000) . In four studies the de®nition of pregnancy was not stated (McClure et al., 1992; Farhi et al., 1993; White et al., 1996; Fulghesu et al., 1997) . Pregnancy rate (per cycle and per patient) was provided for all studies except one (McClure et al., 1993) .
The de®nition of miscarriage, spontaneous abortion or ongoing pregnancy rate was not clearly stated in seven studies (Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . In two studies the de®nition of early pregnancy loss was stated Hamilton-Fairley et al., 1992) . In four studies the de®nition of miscarriage was based on the division in ®rst and second trimester abortions (McClure et al., 1992 (McClure et al., , 1993 Dale et al., 1993 Dale et al., , 1998 . Data on miscarriage rates were stated in all studies except one (Vicino et al., 2000) .
Description of screening characteristics related to treatment outcome
Except for one , all studies stated data of age (means T SD) for patients. In only four studies were exact data of cycle history (i.e. oligomenorrhoea or amenorrhoea) for all patients mentioned Hamilton-Fairley et al., 1992; Farhi et al., 1993; Balasch et al., 1996) . Details of BMI levels for patients were given in nine studies (Dale et al., 1993 Farhi et al., 1993; McClure et al., 1993; Balasch et al., 1996; White et al., 1996; Fulghesu et al., 1997; Yarali et al., 1999; Vicino et al., 2000) . Some studies divided patients into non-obese (lean) and obese [BMI >25 kg/ m 2 Dale et al., 1993 Dale et al., , 1998 White et al., 1996; Fulghesu et al., 1997) , BMI >27 (Vicino et al., 2000) , or probably BMI >30 (Yarali et al., 1999) ]. One study (Strowitzki et al., 1998) described patients as lean or obese without any further information. The fraction of obese (BMI >25) and non-obese patients was calculated where only continuous data of BMI were provided (McClure et al., 1992; Farhi et al., 1993; White et al., 1996) , assuming a normal distribution.
In nine studies, CRA was de®ned as anovulation during b3 consecutive cycles with an increasing dose up to b150 mg/day for a period of 5 days Hamilton-Fairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; Balasch et al., 1996; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . One study decreased the threshold for CRA to 100 mg/day (Fulghesu et al., 1997) . In one study the dose for CRA was not clearly stated (McClure et al., 1992) . CCF was de®ned as failure to conceive after b6 ovulatory clomiphene citrate cycles (McClure et al., 1992; Farhi et al., 1993; Fulghesu et al., 1997; Strowitzki et al., 1998; Yarali et al., 1999) . One study decreased the number of cycles for CCF to 3 (Balasch et al., 1996) . In two other studies the number of ovulatory cycles to ful®l the criteria for CCF were not stated (Dale et al., 1993 . In two studies (McClure et al., 1993; Strowitzki et al., 1998) , patients were said to be (un)responsive or resistant to clomiphene citrate, but the dose as well as the duration of clomiphene citrate treatment were not stated. In only six studies were the exact number of patients suffering from CRA and CCF mentioned Hamilton-Fairley et al., 1992; McClure et al., 1992 McClure et al., , 1993 Dale et al., 1993; Vicino et al., 2000) .
The de®nition of polycystic ovaries was based on the Adams criteria (i.e. increased number of follicles and either an increased ovarian volume or increased stromal area or both) Hamilton-Fairley et al., 1992; Farhi et al., 1993; White et al., 1996; Dale et al., 1998; Strowitzki et al., 1998; Vicino et al., 2000) , or based on the presence of an increased number of follicles and/or ovarian stroma (McClure et al., 1992 (McClure et al., , 1993 . Others did not report (clear) information on the de®nition of polycystic ovaries (Dale et al., 1993; Balasch et al., 1996; Fulghesu et al., 1997; Yarali et al., 1999) . In seven studies the number of patients with polycystic ovaries was stated Hamilton-Fairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; White et al., 1996; Strowitzki et al., 1998) .
Details of baseline testosterone levels were provided in nmol/l Hamilton-Fairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Fulghesu et al., 1997) or converted to SI units when expressed as ng/ml (Farhi et al., 1993; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . Data regarding androstenedione levels were provided in nmol/l (Dale et al., 1993 Fulghesu et al., 1997; Vicino et al., 2000) or converted to SI units (Vicino et al., 2000) .
Details concerning baseline LH levels for patients or subgroups of patients were provided in IU/l in eight studies Hamilton-Fairley et al., 1992; Dale et al., 1993 Dale et al., , 1998 Farhi et al., 1993; Fulghesu et al., 1997; Strowitzki et al., 1998; Vicino et al., 2000) or converted when expressed as mIU/ml (Vicino et al., 2000) . Baseline LH/FSH ratios were provided by eight studies Farhi et al., 1993; Balasch et al., 1996; Fulghesu et al., 1997; Dale et al., 1998; Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) . Dale et al. (1998) assessed insulin resistance and glucose tolerance by means of a continuous infusion of glucose with CIGMA (continuous infusion of glucose with model assessment) model assessment test. Fulghesu et al. (1997) classi®ed patients as hyperinsulinaemic or normoinsulinaemic based on the insulinaemic response to glucose load (OGTT). Both studies (Fulghesu et al., 1997; Dale et al., 1998) provided data of fasting glucose (nmol/l) and insulin levels (mIU/l). Conversion to IU units was performed where necessary.
Pooling of data
Data from studies reporting relationships between initial screening characteristics and outcome parameters of ovulation induction as measures of association (OR) were pooled if at least two studies reported an association of similar screening parameter and outcome characteristic. The measures of association were pooled using the inverse of the variance as weight. Heterogeneity was tested for using the Q statistic as de®ned by DerSimonean and Laird, which has a c 2 distribution with df = (number of pooled studies ± 1) (DerSimonian and Laird, 1986) . Random effects estimates were calculated using the likelihood method described by Hardy and Thompson Table III . Possible clinical and endocrine features involved in the total amount of gonadotrophins administered (IU) during gonadotrophin induction of ovulation in normogonadotrophic anovulatory infertility (see also (1998), when at least three studies were available. Association measures were extracted from studies for the following outcome parameters: total amount of FSH administered (Table III) , cancellation rate (Table IV) , ovulation rate (Table V) , pregnancy rate (Table VI and Table VII ) and miscarriage rate (Table VIII) .
Results of pooling
A total number of seven studies reported an association (all positive) between obesity and total amount of gonadotrophins administered (IU) (Figure 1 ) McClure et al., 1992; Dale et al., 1993 Dale et al., , 1998 ; Fulghesu et al., Table IV . Possible clinical and endocrine features involved in the observed cancellation rate during gonadotrophin induction of ovulation in normogonadotrophic anovulatory infertility (see also 
a Odds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range 25±30 kg/m 2 ). b OR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies). a Odds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range 25±30 kg/ m 2 ). b OR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies). c Indirect calculation of OR: based on continuous data (deducted from ®gure) . d OR calculated based on subdivision of testosterone and LH serum levels (respectively testosterone >2.6 nmol/l or <2.7 nmol/l and LH >11.0 IU/l or <11.1 IU/ l) (White et al., 1996) . e Only ®rst cycle data included in the present analysis (Yarali et al., 1999) . f Pooled OR not calculated because continuous and categorical (White et al., 1996) data were provided by either studies. 
a Odds ratio (OR) and 95% con®dence interval (CI) based on obese versus non-obese patients (applied threshold varied from study to study: range 25±30 kg/m 2 ). b OR based on hyperinsulinaemic versus normoinsulinaemic patients (applied de®nition varied between studies). c Vicino et al. (2000) provides continuous data of BMI for pregnant versus non-pregnant women: assume BMI is normally distributed among pregnant versus non-pregnant women: calculate the fraction obese versus non-obese (2Q2 table constructed): indirect calculation of OR (based on number of cycles): 0.45. d OR calculated based on subdivision of testosterone and LH serum levels (respectively testosterone >2.6 nmol/l or <2.7 nmol/l and LH >11.0 IU/l or <11.1 IU/l) (White et al., 1996) . Farhi et al. (1993) and White et al. (1996) both provide continuous data of BMI for pregnant versus non-pregnant women: assume BMI is normally distributed among pregnant versus non-pregnant patients: calculate the fraction obese and non-obese patients (2Q2 (Farhi et al., 1993; White et al., 1996; Vicino et al., 2000) . f For LH levels expressed as SI units (IU/l) pooled analysis was performed (Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Vicino et al., 2000) .
1997; Strowitzki et al., 1998; Vicino et al., 2000) . The weighted mean difference (WMD) (obese versus non-obese) for total dose used was 771 (95% CI: 700±842) IU. Signi®cant heterogeneity was detected between studies (P < 0.001 (White et al., 1996) . e For LH levels expressed as SI units (IU/l) pooled analysis was performed (McClure et al., 1993; White et al., 1996) . Figure 1 . Association measures between obesity and total amount of gonadotrophins administered (IU) for ovulation induction in normogonadotrophic anovulatory infertility (median and 95% con®dence interval). The weighted mean difference (WMD) was generated using inverse variance weighting. Heterogeneity was tested for and random effects estimates were calculated using the likelihood method as described by Hardy and Thompson (1998) .
produced a WMD (hyperinsulinaemic versus normoinsulinaemic) of 351 (95% CI: 73±630) IU. Four studies reported an association between obesity and cancellation rate (Dale et al., 1993 Strowitzki et al., 1998; Vicino et al., 2000) (Figure 2 ). The pooled OR (obese versus non-obese) was 1.86 (95% CI: 1.13±3.06). Despite con¯icting directions of association, the test for heterogeneity was not signi®cant (P = 0.2).
Four studies Strowitzki et al., 1998; Yarali et al., 1999; Vicino et al., 2000) reported an association between obesity and ovulation rate, with a pooled OR (obese versus non-obese) of 0.44 (95% CI: 0.31±0.61) (Figure 3) . The test for heterogeneity was not signi®cant (P = 0.4). Two studies White et al., 1996) reported an association between LH and ovulation rate. Pooling of the results was not possible because one study reported LH as a continuous variable and the other provided data of LH in two categories (White et al., 1996) . Association measures for respectively testosterone (White et al., 1996) and insulin resistance (Fulghesu et al., 1997) with ovulation were calculated from the data provided.
Pregnancy was analysed per cycle and per patient. Four studies reported an association (three positive and one negative) between obesity and pregnancy rate per cycle, pooled OR (obese versus non-obese) 1.13 (95% CI: 0.70±1.84) (HamiltonFairley et al., 1992; Dale et al., 1993; Strowitzki et al., 1998; Vicino et al., 2000) . The test for heterogeneity was not signi®cant (P = 0.4). Five studies reported an association (two positive and three negative) between obesity and pregnancy rate per patient Farhi et al., 1993; White et al., 1996; Strowitzki et al., 1998; Vicino et al., 2000) . The pooled OR (obese versus non-obese) was 1.22 (95% CI: 0.77±1.93). The test for heterogeneity was not signi®cant (P = 0.16). Three studies (Farhi et al., 1993; White et al., 1996; Vicino et al., 2000) reported an association between testosterone and pregnancy rate per patient. The pooled OR (per nmol/l) was 0.94 (95% CI: 0.80±1.09). Four studies (Farhi et al., 1993; Balasch et al., 1996; White et al., 1996; Vicino et al., 2000) reported an association between LH and pregnancy rate per patient (Figure 4) . The pooled OR (per IU/l) was 1.04 (95% CI: 1.01±1.07). The test for heterogeneity was not possible in the latter two cases. Association measures between insulin resistance and pregnancy rate per cycle as well as per patient (Fulghesu et al., 1997; Dale et al., 1998) were calculated. Both studies (Fulghesu et al., 1997; Dale et al., 1998) reported a negative association between insulin resistance and pregnancy rate, with pooled OR (hyperinsulinaemic versus normoinsulinaemic) of 0.29 (95% CI: 0.10±0.80) and 0.24 (95% CI: 0.08± 0.74).
Four studies reported an association between obesity and miscarriage rate ( Figure 5 ) McClure et al., 1993; White et al., 1996; Strowitzki et al., 1998) . The pooled OR (obese versus non-obese) was 3.05 (95% CI: 1.45±6.44). The test for heterogeneity was not signi®cant (P = 0.17). Two studies (McClure et al., 1993; White et al., 1996) reported an association between LH and miscarriage rate. The pooled OR (per IUl/l) was 1.013 (95% CI: 0.95±1.08). Two studies (Fulghesu et al., 1997; Dale et al., 1998) reported an association between insulin resistance and miscarriage rate. The pooled OR (hyperinsulinaemic versus normoinsulinaemic) was 1.75 (95% CI: 0.30±10.3). An association of age (McClure et al., 1993) versus testosterone (White et al., 1996) and miscarriage rate was calculated from the data provided.
None of the studies provided a measure of association between CRA/CCF or the presence of polycystic ovaries and treatment outcome.
In summary, signi®cant associations were found for the total amount of FSH administered, cancellation rate, ovulation rate and miscarriage rates with BMI. Furthermore, signi®cant associations were found for the total amount of FSH and pregnancy rate with insulin resistance.
Discussion
This systematic review and meta-analysis demonstrates how few studies have provided measures of association between screening characteristics in women with normogonadotrophic anovulatory infertility and gonadotrophin ovulation induction treatment outcome. The studies included used various criteria for patient inclusion and intervention and are prone to bias. The best available evidence suggests that obesity and insulin resistance are both associated with adverse treatment outcomes, including increased FSH requirements, increased cancellation and miscarriage rates and most importantly decreased ovulation and pregnancy rates.
Obesity frequently coincides with normogonadotrophic anovulation and represents an important clinical feature associated with PCOS (Laven et al., 2002) . Differences in pharmacokinetic characteristics of gonadotrophin preparations (Mannaerts et al., 1993) as well as the amount of exogenous gonadotrophins required to achieve follicular maturation McClure et al., 1992; Dale et al., 1993; Vicino et al., 2000; Imani et al., 2002b) related to body weight, have been reported. Obesity is associated with reduced circulating levels of sex hormonebinding globulin (SHBG), mildly elevated androgen levels (Poretsky et al., 1999) and hyperinsuliaemia (Norman et al., 2002) . Insulin resistance [associated with PCOS as well (Dunaif, 1999) ] is also related to the total amount of gonadotrophins administered, as previously reported (Homburg et al., 1996) . So far, the impact of obesity on the cycle cancellation rates in women with anovulatory infertility has not been convincingly established. However, the impact of obesity on ovulation rates was previously mentioned by several authors Yarali et al., 1999; Vicino et al., 2000) . The present metaanalysis explicitly shows that obese women are less likely to ovulate following gonadotrophin ovulation induction and therefore suggests that ovarian dysfunction in these women is more severe. However, differences in absorption and distribution of exogenous FSH may also be involved (Mannaerts et al., 1993) . Weight reduction may normalize insulin resistance and androgen metabolism Holte et al., 1995) and may signi®cantly improve menstrual abnormalities, ovulation, and fertility rates (Norman et al., 2002) .
Obesity does not seem to be associated with decreased pregnancy rates, as previously reported Dale et al., 1993; White et al., 1996; Strowitzki et al., 1998; Vicino et al., 2000) . It should be noted that some of these conclusions were drawn based on studies of a selected group of non-obese women (i.e. BMI <27 kg/m 2 ). The current analysis, however, shows an increased incidence of spontaneous miscarriage with increasing BMI in women with PCOS. This ®nding has been reported before . The present analysis, though, shows that all other studies are in line with this observation. This result again stresses the importance of weight reduction. Likewise, it has been described that the incidence of spontaneous miscarriage increases with decreasing insulin sensitivity . However, the small number of miscarriages precludes de®nitive conclusions in this regard. Along these lines, it has been suggested that insulin-sensitizing agents also reduce miscarriage rates (Glueck et al., 2001 ). Hyperandrogenism is considered to be a key feature in PCOS and constitutes a hallmark for the diagnosis (Dunaif et al., 1992) . Intraovarian inhibitors of FSH action (such as the IGF system) (Schipper et al., 1997; van Dessel et al., 1999) might possibly promote follicle maturation arrest and concomitantly ovarian hyperandrogenism (Giudice, 1999) . Hyperandrogenism has proven to be a powerful predictor for the response to ovulation induction, emphasizing its signi®cance for ovarian dysfunction in these women (Imani et al., 1998 (Imani et al., , 1999 (Imani et al., , 2000 (Imani et al., , 2002a Mulders et al., 2003) . The impact of these biologically plausible factors involved in ovarian dysfunction in normogonadotrophic anovulation, such as serum androgens and free IGF-I, unfortunately could not be scrutinized in the current analysis, because of lack of data.
Elevated LH levels are frequently encountered in PCOS, but this is not a mandatory diagnostic of PCOS (Laven et al., 2002) . Although it was previously reported that elevated serum LH concentrations were associated with increased miscarriage rates on the basis of retrospective studies (Howles et al., 1986; Balen et al., 1993; Watson et al., 1993) , prospective data do not support the concept that elevated LH is implicated in ovarian dysfunction and ovulation induction outcome (Imani et al., 2002a) . The present analysis, however, shows a small but signi®cant association of elevated serum LH with increased pregnancy rates.
Upon pelvic ultrasound, ovaries of women with normogonadotrophic anovulation might be enlarged (Puzigaca et al., 1991; Pache et al., 1992) , contain an increased number of follicles (Obhrai et al., 1990; Jonard et al., 2003) , and exhibit an increased density of ovarian stroma (Dewailly, 1997) . It has been shown that the value of these sonographic parameters as a screening test to predict endocrine abnormalities characteristic of PCOS is limited (van Santbrink et al., 1997) . In addition, sonographic parameters are predictive of patients remaining anovulatory following clomiphene citrate (Imani et al., 1998) . Others recently described a correlation between initial ovarian volume or mean follicle number and subsequent response applying gonadotrophin induction of ovulation (van der Meer et al., 1998; Lass et al., 2002; Mulders et al., 2003) . These ®ndings could not be recon®rmed in the current analysis since none of the included studies reported suf®cient data to perform the analysis.
The association of advanced age with poorer treatment outcome following clomiphene citrate-or FSH-induced cycles, as previously reported (McClure et al., 1993; Imani et al., 2002a; Mulders et al., 2003) , could not be con®rmed by the present meta-analysis because of lack of data.
In summary, the current results are perhaps somewhat disappointing. However, this should not be too surprising as most studies did not intend to predict treatment outcome by patient characteristics. The possibility that some conclusions from this analysis may be affected by the repetitive inclusion of data cannot be completely discarded. However, we believe that such effects, if they exist, are minor. In addition, pooling of the original data ®les rather than the published data might also have resulted in slightly different outcomes. Principally, the association between initial clinical screening parameters (re¯ecting the extent of ovarian dysfunction in normogonadotrophic anovulatory infertility) and treatment outcome deserves further attention. In addition, more individualized ovulation induction treatment algorithms may subsequently be developed. For the future, there is a need to standardize the de®nitions of ovulation induction treatment outcome in women with normogonadotrophic anovulatory infertility (including PCOS). Live-birth from a singleton pregnancy following gonadotrophin induction of ovulation could then be more effectively achieved by treatment strategies individually tailored on the basis of initial screening characteristics.
